Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Bladder cancer is one of the more common cancers ... Initial results with gemcitabine (Gem) and mitomycin C (MMC) appeared promising but shortages in MMC led to the need to substitute docetaxel ...

These studies indicate that administration of low-dose cisplatin and gemcitabine is safe and feasible in bladder cancer patients with impaired renal function and shows adequate levels of efficacy.

The gemcitabine and cisplatin combination has ... chemotherapy regimen in elderly patients with muscle-invasive bladder cancer. Notwithstanding all of the above considerations, many have indicated ...

The phase 3 NIAGARA trial evaluated this regimen in cisplatin-eligible patients with muscle-invasive bladder cancer, relative to neoadjuvant gemcitabine–cisplatin and surgery alone. Event-free ...

Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration ...

The SunRISe-2 study, in people with muscle-invasive bladder cancer (MIBC ... it it is being used to deliver the chemotherapy agent gemcitabine. In a statement, J&J said that the trial – which ...

There are many treatment options for bladder cancer, which vary depending on the stage and type of bladder cancer you have, your overall health, and your preferences. These include various types ...

You get bladder cancer when bladder cells become abnormal and grow out of control. Over time, a tumor forms. To find out whether you have bladder cancer, the first thing your doctor probably will ...

Bladder cancer affects over 52,000 men and women in the United States on an annual basis, and more than 12,000 people die each year from this disease. It is the fourth most common cancer in men in ...